News · 26 weeks670%
2026-04-192026-10-11
Mix2390d
- Other9(39%)
- Insider5(22%)
- Analyst3(13%)
- Earnings3(13%)
- SEC Filings3(13%)
Latest news
25 items- PRInsmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)——New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management——Phase 3b ENCORE Study Findings at IDWeek 2026 Examine Amikacin and Macrolide Resistance Development in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease—BRIDGEWATER, N.J., Oct. 14, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to del
- ANALYSTInsmed downgraded by Wolfe ResearchWolfe Research downgraded Insmed from Outperform to Peer Perform
- SECInsmed Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Announces CFO Transition—Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership——Company Reaffirms Full-Year 2026 Financial Guidance——Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026—BRIDGEWATER, N.J., Oct. 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Sara Bonstein will step down as Chief Financial Officer (CFO). Ms. Bonstein will continue to serve as CFO until October 30, 2026, to ensure a smooth transition through
- ANALYSTGoldman resumed coverage on Insmed with a new price targetGoldman resumed coverage of Insmed with a rating of Buy and set a new price target of $188.00
- PRFDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study——Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikacin liposome inhalation suspension) for the treatment of Myco
- PRInsmed Expands Community Impact During Fifth Annual Global Day of GoodCompany-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its fifth annual Global Day of Good, a company-wide day of service during which employees volunteer simultaneously in their respective communities around the world. This year's day of service is the Company's largest and most far-reaching yet, with 1,350 employees across the U.S., Europe, and Japa
- INSIDERDirector Brennan David R sold $3,100,000 worth of shares (25,000 units at $124.00), decreasing direct ownership by 39% to 39,238 units (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commenc
- PRInsmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026—New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease——New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via COMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)—BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation
- PRInsmed to Present at September 2026 Investor ConferencesBRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website a
- PRBRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease—First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage—BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI® (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older. BRINSUPRI, t
- INSIDERDirector Sharoky Melvin Md sold $637,650 worth of shares (5,000 units at $127.53) (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Operating Officer Adsett Roger sold $31,964,810 worth of shares (239,850 units at $133.27) and exercised 239,850 shares at a strike of $20.45 (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- INSIDERChief Medical Officer Flammer Martina M.D. exercised 27,173 shares at a strike of $21.20 and sold $3,494,838 worth of shares (27,173 units at $128.61) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insmed IncorporatedSCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
- SECInsmed Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Reports Second-Quarter 2026 Financial Results and Provides Business Update—Total Company Revenues of $425.5 Million for the Second Quarter of 2026——BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026——ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth Over the Second Quarter of 2025——Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion——Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million——Company Raises Peak Revenue Estimate for its Three Lead Programs to More than $14 Billion Total——Peak Revenue Estimate Consists of More than $7 Billion for BR
- SECSEC Form 10-Q filed by Insmed Incorporated10-Q - INSMED Inc (0001104506) (Filer)
- INSIDERChair and CEO Lewis William exercised 10,700 shares at a strike of $24.94 and sold $1,134,890 worth of shares (10,700 units at $106.06) as part of a pre-agreed trading plan (SEC Form 4)4 - INSMED Inc (0001104506) (Issuer)
- PRInsmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss financial results and provide a business update.Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Insmed IncorporatedSCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
- ANALYSTBMO Capital Markets initiated coverage on Insmed with a new price targetBMO Capital Markets initiated coverage of Insmed with a rating of Outperform and set a new price target of $192.00
- SECInsmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSMED Inc (0001104506) (Filer)
- PRInsmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension–12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12––TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study––These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH––Insmed to Host Investor Call Thursday, July 16, 2026, at 8:00 a.m. ET–BRIDGEWATER, N.J., July 16,
INSM FAQ
6 questionsWhat does Insmed Incorporated do?
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the...Where does INSM stock trade?
Insmed Incorporated (INSM) is listed on NASDAQ.What sector and industry is INSM in?
Insmed Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INSM?
Insmed Incorporated has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-10-12.What companies are similar to INSM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INSM side-by-side with any of them on Quantisnow.How can I track INSM on Quantisnow?
Quantisnow aggregates Insmed Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INSM to receive live email and push alerts on every new disclosure.